Eli Lilly and Company (LLY) Shares Sold by Prudential Financial Inc.
Prudential Financial Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,350,908 shares of the company’s stock after selling 24,370 shares during the quarter. Prudential Financial Inc. owned approximately 0.13% of Eli Lilly and worth $111,179,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in LLY. Heritage Trust Co bought a new stake in Eli Lilly and in the first quarter valued at about $135,000. Point72 Asia Hong Kong Ltd increased its holdings in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Eli Lilly and in the second quarter valued at about $148,000. Cornerstone Advisors Inc. increased its holdings in Eli Lilly and by 18.4% in the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after buying an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC increased its holdings in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the last quarter. 75.53% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on LLY. Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Oppenheimer Holdings, Inc. lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective for the company. in a report on Wednesday, July 26th. BMO Capital Markets reissued an “underperform” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 26th. Jefferies Group LLC reissued a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, Leerink Swann lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $93.00 to $90.00 in a report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $88.97.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 990,000 shares of company stock worth $82,949,650 over the last ninety days. Insiders own 0.20% of the company’s stock.
Eli Lilly and Company (NYSE LLY) opened at 87.23 on Friday. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09. The firm has a market capitalization of $92.03 billion, a P/E ratio of 37.75 and a beta of 0.34. The stock’s 50 day moving average price is $84.38 and its 200 day moving average price is $82.29.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. On average, analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.38%. Eli Lilly and’s dividend payout ratio is 90.04%.
WARNING: This article was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/10/21/eli-lilly-and-company-lly-shares-sold-by-prudential-financial-inc.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.